Research

rs9420907 — OBFC1

Intronic variant in the CST complex component STN1/OBFC1 that influences telomere length; the C allele drives longer telomeres and elevated cancer risk while the A allele predisposes to shorter telomeres and accelerated cellular aging

Strong Risk Factor Share

Details

Gene
OBFC1
Chromosome
10
Risk allele
A
Consequence
Regulatory
Inheritance
Additive
Clinical
Risk Factor
Evidence
Strong
Chip coverage
v3 v4 v5

Population Frequency

AA
75%
AC
22%
CC
3%

Ancestry Frequencies

african
53%
latino
15%
european
14%
south_asian
10%
east_asian
2%

See your personal result for OBFC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Chromosome Guardian — OBFC1 and the Telomere Length Paradox

Your chromosomes end in telomeres — repetitive DNA caps that protect genetic information from fraying like the plastic tips on shoelaces. Every time a cell divides, telomeres shorten slightly, acting as a molecular clock that limits how many times a cell can replicate. When telomeres reach a critical short length, cells enter senescence or die, a process thought to drive much of what we call aging. The OBFC1 gene encodes [STN1 | Suppressor of cdc Thirteen 1], a subunit of the CST complex (CTC1-STN1-TEN1) that caps telomere ends, recruits DNA polymerase alpha for C-strand fill-in synthesis, and counterbalances telomerase to prevent runaway telomere elongation. The rs9420907 variant sits in an intron of OBFC1 and affects how efficiently this capping mechanism operates — with consequences running in two directions at once.

The Mechanism

Rs9420907 is an intronic regulatory variant at 10q24.33 within OBFC1, located on the forward strand at GRCh38 position 103,916,707. It does not alter the STN1 protein directly, but sits in a region assigned a RegulomeDB score of 3a — indicating probable transcription factor binding site activity in a DNase I-hypersensitive region. Altered transcription factor affinity likely modulates OBFC1 mRNA levels, which in turn shifts the balance of the CST complex at telomere ends.

When OBFC1/STN1 levels are reduced (A-allele pattern), CST-mediated C-strand fill-in is less efficient after each round of telomerase extension. The result: telomeres grow shorter faster. Depletion of hSTN1 in human somatic cells11 Depletion of hSTN1 in human somatic cells
Huang C et al. Human Stn1 protects telomere integrity by promoting efficient lagging-strand synthesis at telomeres. Cell Research, 2012
causes catastrophic telomere shortening, DNA damage response activation, and premature cellular senescence — a cellular blueprint for accelerated aging. The C allele appears to maintain or increase OBFC1 expression, preserving telomere length but also — paradoxically — allowing cancer cells greater replicative freedom.

The Evidence

The original GWAS discovery22 original GWAS discovery
Levy D et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. PNAS, 2010
in 3,417 participants identified rs9420907 as genome-wide significant (P = 2.0×10⁻⁸), with the A allele coding for shorter leukocyte telomere length (β = −0.11 standard deviations per allele, equivalent to approximately 83 base pairs).

The finding was powerfully confirmed in a meta-analysis of 37,684 individuals33 meta-analysis of 37,684 individuals
Codd V et al. Identification of seven loci affecting mean telomere length and their association with disease. Nature Genetics, 2013
. OBFC1 emerged as one of five confirmed telomere-biology loci, alongside TERT, TERC, NAF1, and RTEL1 — each encoding a protein directly involved in telomere maintenance. The seven-locus genetic risk score for shorter telomeres was associated with a 21% increase in coronary artery disease risk per standard deviation reduction in telomere length (P = 0.014, across 22,233 cases and 64,762 controls).

The paradox deepens with cancer data. The C allele44 The C allele
Speedy HE et al. Genetic variation associated with longer telomere length increases risk of CLL. Cancer Epidemiology, Biomarkers & Prevention, 2016
— which gives longer telomeres — increases CLL risk (OR 1.36, 95% CI 1.08–1.71), and a separate study found OBFC1-rs9420907-C associates with myeloproliferative neoplasm risk55 OBFC1-rs9420907-C associates with myeloproliferative neoplasm risk
Cordone I et al. Genetic polymorphisms and MPN risk. Blood Cancer Journal, 2020
with an OR of 1.43 (95% CI 1.15–1.77), and with multiple myeloma risk (OR 1.32, 95% CI 1.12–1.55). This mirrors the pattern seen at the TERT locus: longer telomeres protect against degenerative aging but allow cancer cells to replicate unchecked.

Crucially, rs9420907 shows extreme population stratification. The C allele is present at ~14% in Europeans and ~15% in Latinos, but reaches ~53% in African populations and is nearly absent (~1.6%) in East Asians — where the locus is effectively monomorphic. This means the variant's effects on aging and disease risk are most relevant for people of European and African descent.

Practical Implications

For AA homozygotes (short-telomere genotype), the key concern is accelerated cellular aging: shorter average leukocyte telomere length at any given age, modestly elevated cardiovascular disease risk, and the general health consequences of faster biological clock ticking. The actionable response is to preserve telomere length through lifestyle: aerobic exercise has the most consistent evidence for telomere preservation, alongside adequate omega-3 intake, stress reduction, and avoidance of smoking and excess alcohol.

For C-allele carriers, the picture is more nuanced. Longer telomeres are generally protective against age-related disease, but carriers of one or two C alleles face modestly elevated risk for hematologic malignancies (CLL, MPN, multiple myeloma). This does not warrant alarm — the absolute risk increase is small — but it supports attentiveness to unexplained fatigue, lymphadenopathy, or abnormal blood counts, and adherence to standard cancer screening protocols.

Interactions

OBFC1 rs9420907 operates within the broader telomere-length regulatory network. The strongest pathway partners are rs2736100 in TERT66 rs2736100 in TERT
the telomerase catalytic subunit
, rs16847897 in TERC77 rs16847897 in TERC
the telomerase RNA template
, and rs12696304 in TERC88 rs12696304 in TERC
second independent TERC signal
. These loci act additively — people who inherit short-telomere alleles at multiple loci have substantially shorter telomeres than those with only one variant, and correspondingly higher cardiovascular risk.

The FOXO3 longevity variant rs280229299 rs2802292
the most replicated human longevity locus
is mechanistically connected: FOXO3 G-allele carriers show higher telomerase activity and better telomere protection with age, suggesting FOXO3 may partially compensate for short-telomere genotypes at OBFC1 and TERT. No formal interaction study has tested this combination, but the mechanistic overlap is plausible and worth investigating in future research.

Genotype Interpretations

What each possible genotype means for this variant:

AC “Balanced Telomere Length” Intermediate Caution

One copy of the long-telomere allele — elevated cancer vigilance warranted

Heterozygous AC individuals occupy the middle ground of the telomere-length spectrum at this locus. The per-allele effect on telomere length is approximately 83–170 base pairs, so AC individuals have intermediate telomere length between AA and CC homozygotes.

The elevated cancer risk associated with the C allele comes from the principle that longer telomeres allow more cell divisions before replicative senescence — giving pre-cancerous clones more chances to acquire additional mutations. Studies have found C-allele carriers have OR ~1.36 for CLL, OR ~1.32 for multiple myeloma, and OR ~1.43 for myeloproliferative neoplasms compared to AA individuals.

The overall absolute risk remains low — these are common-variant effect sizes reflecting population-level statistics, not individual destiny. Most C-allele carriers will never develop these cancers. However, being alert to relevant symptoms and maintaining standard blood testing is prudent.

AA “Short Telomere Genotype” Reduced Caution

Shorter telomeres and modestly elevated aging-related disease risk

The A allele at rs9420907 is associated with reduced OBFC1/STN1 expression or function, impairing C-strand fill-in synthesis after telomerase extends telomere G-overhangs. The net result is shorter average leukocyte telomere length — estimated at approximately 83–170 base pairs shorter per A allele compared to carrying a C allele. This may sound small, but telomere length differences compound over decades of cell division.

A genome-wide meta-analysis of 37,684 individuals combined seven telomere-length loci including OBFC1 into a genetic risk score and found that individuals with more short-telomere alleles had a 21% increase in coronary artery disease risk per standard deviation reduction in telomere length. OBFC1 rs9420907 contributes approximately one seventh of that polygenic signal.

The cardiovascular risk mechanism likely operates through telomere-induced cellular senescence in vascular cells — shorter telomeres in endothelial and smooth muscle cells accelerate the aging of blood vessel walls, promoting atherosclerosis. The same mechanism may affect other long-lived cell populations including neurons and immune cells.

CC “Long Telomere Genotype” High Risk Warning

Longest telomeres at this locus — strong protection against aging but elevated hematologic cancer risk

CC homozygotes have the maximum OBFC1-driven telomere length at this locus — roughly 170 base pairs longer than AA individuals on average. Per-allele odds ratios for hematologic cancers compound in CC individuals: the OR for myeloproliferative neoplasms in homozygous C carriers reaches 2.42 (95% CI 1.33–4.38) in the most comprehensive study. For CLL, OR estimates per allele of ~1.36 imply CC homozygotes face roughly 1.85-fold increased risk compared to AA.

These are meaningful risk elevations. The underlying biology is that longer telomeres in hematopoietic stem cells allow more rounds of clonal expansion — giving rare cells that acquire pro-leukemic mutations more replicative cycles before entering senescence. This explains why genetically long telomeres protect against solid tumors driven by chromosomal instability, but elevate risk for clonal hematologic diseases driven by clonal expansion.

On the aging side, CC individuals have a genuine biological advantage: better-preserved vascular and immune cell telomere length, contributing to the reduced cardiovascular risk seen in the seven-locus telomere GWAS meta-analysis.

Key References

PMID: 20421499

Genome-wide association in 3,417 individuals identifies OBFC1/rs9420907 as an independent telomere-length locus; A allele associates with shorter telomeres (β = −0.11, P = 2.0×10⁻⁸)

PMID: 23535734

Seven-locus GWAS meta-analysis (37,684 subjects) confirms OBFC1 at 10q24.33 as one of five telomere-biology genes influencing mean leukocyte telomere length

PMID: 27197291

C allele of rs9420907 associates with increased CLL risk (OR 1.36, 95% CI 1.08–1.71) via genetically longer telomeres

PMID: 32873778

OBFC1-rs9420907-C shows suggestive association with myeloproliferative neoplasm risk (OR 1.43, 95% CI 1.15–1.77); per-allele effect on telomere length ~170 bp

PMID: 24904205

rs9420907 is monomorphic (AA only) in Han Chinese; allele confirmed present in European and African populations, highlighting strong population stratification at this locus